The independent source for health policy research, polling, and news.
2,301 - 2,320 of 3,883 Results
Premature death, a dearth of treatments, mistreatment in emergency rooms and a woeful lack of funding are just a few of the problems confronting people with sickle cell disease.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Each hospital will have its payments reduced by 1 percent for the year.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Patients are often aggressively screened for cancer, even if they won’t live long enough to benefit.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
These accounts are exempt from taxes and linked to high-deductible health plans. Republicans tried last summer in their unsuccessful efforts to replace the health law to make the accounts more enticing for consumers, but they didn’t make those changes in the current tax bill.
It’s a regular part of the politically charged debate over health care. But the lines sometimes blur between rhetoric and how Canada’s system actually works.
American single-payer advocates want to emulate Canada’s system. But many Canadian experts say the U.S. first needs to address some basic questions.
Genetic testing firms declare bankruptcy and wipe out debt to the federal government.
Hospitals are jockeying for patients and view the many different quality and safety ratings as a keen way to distinguish their services. But when those ratings nosedive, a hospital may retaliate.
Doctors prescribed powerful opioids for a patient after back surgery but gave her little guidance on how to take them safely. Then, she says, they misdiagnosed her withdrawal symptoms. Some experts say this situation is akin to a hospital-acquired condition.
Based on research conducted at the University of Michigan’s medical center, a group of surgeons developed a strategy to help post-surgical patients from misusing or abusing their prescription painkillers.
Even though consumers don’t expect to pay for faulty service or goods, they are often forced to pay for bad health care. But a small number of hospitals and doctors are seeking to change that practice.
What will the mega-merger mean for consumers and the health care industry? Senior correspondent Chad Terhune offers insight.
An explosive report prepared by a SynerMed executive alleges the California firm, which oversaw care for 1.2 million patients, fabricated documents and violated state and federal regulations for years. The state says it left low-income patients on Medicaid managed care in “imminent danger.”
Behavioral care was four times more likely to be out-of-network than medical or surgical care, an analysis by Milliman shows.
© 2026 KFF